GSK and Hengrui Pharma Forge $500 Million China Collaboration
Key Points: 1. GSK paid $500 million upfront for global development rights to Hengrui’s portfolio of up to 12 early-stage assets. 2. Includes a PDE3/4 inhibitor for COPD plus programs in oncology, respiratory, immunology, and inflammation. On July 28, 2025, GSK announced a $500 million upfront agreement with China’s Jiangsu Hengrui, with a potential total […]
The post GSK and Hengrui Pharma Forge $500 Million China Collaboration first appeared on 2 Minute Medicine.Source: 2 Minute Medicine